Intuitive Surgical (NASDAQ: ISRG) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $2.4 billion and adjusted earnings of ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.

Intuitive Surgical (NASDAQ: ISRG) capped off a record-breaking 2024 with a blowout fourth-quarter earnings report. For the period ended Dec. 31, the medical technologies (medtech) giant delivered ...

Below is Validea's guru fundamental report for INTUITIVE SURGICAL, INC. (ISRG). Of the 22 guru strategies we follow, ISRG rates highest using our P/B Growth Investor model based on the published ...

Intuitive Surgical (NASDAQ: ISRG), best known for its flagship da Vinci robot, is the global leader in the robotic surgery ...

Investors with a lot of money to spend have taken a bearish stance on Intuitive Surgical (NASDAQ:ISRG). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Intuitive Surgical (NASDAQ: ISRG) is a healthcare company that makes robotic-assisted surgical devices. Its da Vinci surgical systems can assist surgeons make minimally invasive and precise ...

Below is Validea's guru fundamental report for INTUITIVE SURGICAL, INC. (ISRG). Of the 22 guru strategies we follow, ISRG rates highest using our Multi-Factor Investor model based on the published ...

In this article, we will take a look into Intuitive Surgical Inc's (NASDAQ:ISRG) DCF analysis, a reliable and data-driven ...

Investors in Intuitive Surgical Inc (Symbol: ISRG) saw new options become available today, for the March 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Shares of Intuitive Surgical (NASDAQ: ISRG) were pulling back today as a strong fourth-quarter earnings report didn't seem to be enough to justify the medical device maker's lofty valuation.

Intuitive Surgical ISRG reported fourth-quarter 2024 adjusted earnings per share (EPS) of $2.21, which beat the Zacks Consensus Estimate of $1.65 by 24.9%. The bottom line improved 38.1% year over ...